Oxford-AstraZeneca Begins ‘Vaccine Trial’ for Beta Form of Corona | Oxford-AstraZeneca Begins Testing Vaccine for Beta Form of Corona

London: Oxford University said on Monday that it has started a new phase of vaccination in human trials of a vaccine to control the beta form of the corona virus. This form of the virus was first found in South Africa. According to the University of Oxford, which is conducting research in collaboration with AstraZeneca, the AZD 2816 ‘booster’ vaccine will be given to volunteers against the B.1.351 form.

The trial will involve approximately 2,250 participants from the UK, South Africa, Brazil and Poland. For this study, participants will have to take two doses of an approved COVID vaccine.

Professor Sir Andrew J Pollard, lead researcher and director of the Oxford Vaccine Group at the University of Oxford, said that ‘booster’ dose testing of existing vaccines and new types of vaccines is important to ensure that we are well prepared to stay ahead of the coronavirus pandemic. Well prepared.

AZD 2816 to be given in two doses spaced four or 12 weeks apart

The AZD 2816 vaccine will be administered to people who have already received two doses of the original Oxford-AstraZeneca vaccine or mRNA vaccines such as Pfizer-BioNtech. For those who have not been vaccinated, AZD 2816 will be given in two doses at four or 12 weeks apart, or as a second dose four weeks after the first dose of the original Oxford-AstraZeneca vaccine.